The economic promise of developing and implementing dengue vaccines: Evidence from a systematic review

Endo, Iara C.; Ziegelmann, Patrícia Klarmann; Patel, Anita

doi:10.1016/j.vaccine.2016.10.037

Cited by 8 publications

(3 citation statements)

References 41 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…24 Because an economic evaluation study is required by the government or insurance companies as a consideration on decision-making process, it should be comprehensively conducted to enable policy makers to make decisions more precisely while allocating resource and budget because in some countries, such as in Southeast Asian countries, dengue vaccination might be heavily subsidized by the government and would have an impact on healthcare policies. 49 The results on CEA of dengue vaccine in this study demonstrated that dengue vaccine can be considered as a cost-effective intervention, which might be developed and implemented in all regions. 50 It has been highlighted that the total cost of using dengue vaccine in Southeast Asia would be approximately $81.7 million annually, which could save $72.7 million compared with conventional treatment.…”

Section: Discussionmentioning

confidence: 67%

Economic Evaluations of Dengue Vaccination in the Southeast Asia Region: Evidence From a Systematic Review

Supadmi

Suwantika

Perwitasari

et al. 2019

Value in Health Regional Issues

View full text Add to dashboard Cite

Objectives: To review the literature on the cost-effectiveness of dengue vaccination in Southeast Asian countries and possibly to provide recommendations on promoting dengue vaccination in this region. Methods: A systematic search was conducted to identify relevant articles in 3 major databases (ProQuest, American Society of Tropical Medicine and Hygiene, and PubMed). Complete economic evaluation studies, including willingness-to-pay (WTP) studies, that were conducted in any Southeast Asian country were included in this study. Systematic review, nonefull-text, and non-English studies were specifically excluded. Results: Nine selected studies highlighted the economic evaluation of dengue vaccination in Southeast Asian countries by considering many parameters (eg, vaccine cost, vaccine efficacy, cost-effectiveness threshold, economic assessment, public acceptance, and WTP). All studies confirmed that dengue vaccine can be used as a prevention strategy to reduce the incidence rate of dengue cases by providing a variance of high cost-effectiveness values. In addition, communities provided a good assessment, acceptance, and WTP value for the vaccine. Conclusions: The use of dengue vaccine could reduce the burden of disease and economic burden due to dengue infection in Southeast Asian countries. The efficacy of dengue vaccine was estimated to be 50-95% for those <9 years, 9 years, and >9 years. In particular, several studies reported that dengue vaccine could be categorized as a cost-effective intervention in Southeast Asian countries within certain conditions.

show abstract

Section: Discussionmentioning

confidence: 67%

Economic Evaluations of Dengue Vaccination in the Southeast Asia Region: Evidence From a Systematic Review

Supadmi

Suwantika

Perwitasari

et al. 2019

Value in Health Regional Issues

View full text Add to dashboard Cite

show abstract

“…Hence, the introduction of a dengue vaccine may be able to tackle this issue. A study by Endo, Ziegelmann & Patel (2016), concluded that the reduction of the disease and economic burden by the introduction of a dengue vaccine could be substantial especially in dengue endemic areas, hence, may be economically advantageous when compared to other strategies of vector control alone (Endo, Ziegelmann, & Patel, 2016).…”

Section: Ijphcsmentioning

confidence: 99%

Willingness to Pay for Dengue Vaccine and Its Associated Factors Among Healthcare Workers in Petaling Health District

Arifah¹,

Lim²,

Juni

2018

IJPHCS

View full text Add to dashboard Cite

Background: Dengue vaccine can assist in controlling the rise of dengue. Highly effective cost of dengue vaccine in Malaysia is estimated to be between RM50 to RM200 per dose. It is important to know the willingness to pay (WTP) for the vaccine to assist in policy-making decisions for future dengue vaccine programme. The aim of study was to determine willingness to pay for dengue vaccine among healthcare workers (HCW) in Petaling Health District. Materials and Methods: A cross-sectional study was conducted among HCWs of Petaling Health District, Selangor from September to July 2018 via simple random sampling according to proportion of HCWs in specific facilities. A self-administered questionnaire using the contingent valuation method was used to estimate WTP. Factors associated with WTP for dengue vaccine were assessed and associations measured using Chi-square test with significance level at 0.05. Results and Discussion: Response rate was 92.2%. Majority of the respondents were female (72.3%), presently married (73.4%) with 93.6% aged 40 years or less, having at least college or matriculation education (54.3%). For monthly household income, 51.1% was between RM 3001 to RM 9000. Only 17.0% had history of dengue with 43.1% having family history of dengue. The median WTP for dengue vaccine was RM 20 per dose ranging between RM1 to RM500. Among the HCWs, 51.1% had a high WTP for dengue vaccine defined as at or above the median WTP. Factors significantly associated with WTP for dengue vaccine were monthly household income (χ2=11.974, p=0.003), dengue preventive practice (χ2=4.715, p=0.03), knowledge of dengue vaccine (χ2=3.062, p=0.05) and perception towards vaccination (χ2=5.593, p=0.02). Conclusion: The study revealed that the range of WTP for dengue vaccine among healthcare workers was RM 1 to RM 500; with 51.1% of HCWs of Petaling Health District having high WTP for dengue vaccine. The predictors for WTP for dengue vaccine were monthly household income, knowledge regarding dengue vaccine, dengue preventive practice and perception towards vaccination.

show abstract

“…Two serotypes DEN1 and DEN2 are mostly isolated although the other two are also known to be prevalent in neighboring countries [4]. Efforts to curb the rapid progression of the disease by using a vaccine are underway [5][6]. Ocular manifestations of dengue fever have been reported in various countries of the endemic regions; subconjunctival, vitreous, preretinal and retrobulbar hemorrhages, maculopathy, vascular occlusions, and uveitis have been reported as the main clinical features [7][8][9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Pars Plana Vitrectomy for a Sub-Internal Limiting Membrane Hemorrhage and Vitreous Hemorrhage Secondary to Dengue Fever: A Case Report

Malek¹,

Niyonzima²,

Pathan³

et al. 2022

Cureus

View full text Add to dashboard Cite

Although rare, dengue fever-associated ocular manifestations are a valid cause of visual impairment. Clinicians usually have a dilemma between vitrectomy and medical management if there is an associated vitreous hemorrhage. Vitrectomy has been rarely reported previously in the management of vitreous hemorrhage secondary to dengue fever.We report a case of a young adult who presented with bilateral vitreous hemorrhages. The diagnosis of dengue was confirmed by serology and a typical epidemiological context. The patient presented already having undergone yttrium aluminum garnet (YAG) laser hyaloidotomy for preretinal hemorrhage in the other eye, with a subsequent vitreous spread of the hemorrhage. Vitrectomy with internal limiting membrane (ILM) peeling was performed for the affected eye and the visual acuity was fully regained after a few weeks.Dengue fever can present with dense or sub-ILM hemorrhages. In our case, the vision quickly recovered after vitrectomy and ILM peeling. We, therefore, recommend early vitrectomy in cases with vitreous hemorrhage associated with sub-ILM involvement so as not to delay visual recovery.

show abstract

The economic promise of developing and implementing dengue vaccines: Evidence from a systematic review

Cited by 8 publications

References 41 publications

Economic Evaluations of Dengue Vaccination in the Southeast Asia Region: Evidence From a Systematic Review

Economic Evaluations of Dengue Vaccination in the Southeast Asia Region: Evidence From a Systematic Review

Willingness to Pay for Dengue Vaccine and Its Associated Factors Among Healthcare Workers in Petaling Health District

Pars Plana Vitrectomy for a Sub-Internal Limiting Membrane Hemorrhage and Vitreous Hemorrhage Secondary to Dengue Fever: A Case Report

Contact Info

Product

Resources

About